Rekrutierungszahlen
emovis ist nicht nur bekannt für seine hohen Rekrutierungszahlen. Sondern vor allem auch für die Einhaltung bzw. das Übertreffen von prognostizierten Rekrutierungsraten an Studienteilnehmern. Der Grund: zum einen zeigt emovis viel Erfahrung und Innovationsbereitschaft in der Rekrutierung von Patienten, zum andern hat die emovis-Geschäftsführung schlicht die Gewohnheit, Rekrutierungszahlen konservativ zu schätzen. Für emovis ein Gebot der Fairness. Nicht wenige Auftraggeber waren bis dato schon verblüfft – und erfreut.
Suche nach vergangenen Studien und Rekrutierungszahlen
| Start | Indikation | Sponsor | Zeitraum | Rekrutiert | Studiennummer |
|---|---|---|---|---|---|
| 2006 | RLS (Syndrom der unruhigen Beine) | Boehringer Ingelheim Pharma GmbH & Co. KG | 7 Monate | 21 | EudraCT-2005-006128-13 |
| 2009 | Verhütung | Bayer Health Care AG | 9 Monate | 153 | EudraCT-2009-010599-45 |
| 2009 | Depression | Steigerwald Arzneimittelwerk GmbH | 8 Monate | 95 | EudraCT-2008-001417-26 |
| 2006 | Reizdarmsyndrom | GlaxoSmithKline PLC | 3 Monate | 28 | k.A. |
| 2006 | Depression | AstraZeneca PLC | 4 Monate | 13 | EudraCT-2005-003745-14 |
| 2006 | Generalisierte Angststörung | AstraZeneca PLC | 9 Monate | 7 | EudraCT-2005-005055-18 |
| 2006 | RLS (Syndrom der unruhigen Beine) | Axxonis Pharma AG | 10 Monate | 26 | EudraCT-2004-001589-42 |
| 2012 | Depression | Institut de Recherches Internationales Servier | k.A. | 24 | EudraCT-2010-024191-25 |
| 2006 | Schlafstörung | SANOFI-SYNTHELABO RECHERCHE | 18 Monate | 31 | EudraCT-2005-003082-16 |
| 2006 | RLS (Syndrom der unruhigen Beine) | UCB (Schwarz Pharma) | 6 Monate | 21 | EudraCT-2005-000428-18 |
| 2006 | RLS (Syndrom der unruhigen Beine) | UCB (Schwarz Pharma) | 2 Monate | 11 | EudraCT-2005-0022611-25 |
| 2006 | Depression | Sanofi-Aventis Recherche & Développement | 4 Monate | 42 | EudraCT-2004-002327-41 |
| 2004 | Alzheimer | Sanofi | k.A. | 4 | GDCT0030961 |
| 2006 | Depression | Institut de Recherches Internationales Servier | 3 Monate | 46 | EudraCT-2004-004009-10 |
| 2004 | RLS (Syndrom der unruhigen Beine) | UCB (Schwarz Pharma), Imerem GmbH | 6 Monate | 20 | k.A. |
| 2006 | Depression | GlaxoSmithKline PLC | 3 Monate | 21 | EudraCT-2006-001877-13 |
| 2004 | Diabetische Neuropathie | UCB (Schwarz Pharma) | k.A. | 13 | k.A. |
| 2005 | Panikstörung | Elbion AG | 1 Monat | 12 | EudraCT-2005-005708-17 |
| 2003 | Depression | Dr. Willmar Schwabe GmbH & Co. KG | k.A. | 4 | k.A. |
| 2005 | Bronchitis | Bionorica SE | 2 Wochen | 3 | EudraCT-2005-003249-15 |
| 2005 | Prämenstruelles Syndrom | Pfizer Inc. | 8 Monate | 3 | EudraCT-2004-005173-27 |
| 2019 | Grippe-Impfung | Sanofi Pasteur SA | 1 Monat | 99 | EudraCT-2019-000655-14 |
| 2005 | Depression | Eli Lilly and Company, Boehringer Ingelheim Pharma GmbH & Co. KG | 7 Monate | 9 | EudraCT-2004-000167-95 |
| 2005 | Generalisierte Angststörung | Eli Lilly and Company, Boehringer Ingelheim Pharma GmbH & Co. KG | 8 Monate | 17 | EudraCT-2004-002626-22 |
| 2021 | Diabetische Neuropathie | Bayer AG | 4 Monate | 8 | EudraCT-2020-002066-14 |
| 2005 | Reizdarmsyndrom | Astellas Pharma Inc., Yamanouchi Europe B.V. | 2 Monate | 12 | EudraCT-2004-003880-61 |
| 2019 | Clostridium difficile | Pfizer Inc. | 18 Monate | 20 | EudraCT-2016-003866-14 |
| 2005 | Depression | GlaxoSmithKline PLC | 2 Monate | 1 | EudraCT-2004-003803-19 |
| 2016 | Herpes Zoster-Impfung | GlaxoSmithKline PLC | 4 Monate | 11 | EudraCT-2015-001778-17 |
| 2004 | Generalisierte Angststörung | Eli Lilly and Company, Boehringer Ingelheim Pharma GmbH & Co. KG | 10 Monate | 14 | k.A. |
| 2004 | Soziale Phobie | GlaxoSmithKline PLC | 5 Monate | 35 | EudraCT-2004-000848-24 |
| 2021 | COVID-19 | Heidelberg ImmunoTherapeutics GmbH | aktiv | 35 | k.A. |
| 2004 | Reizdarmsyndrom | GlaxoSmithKline PLC | 5 Monate | 49 | EudraCT-2004-000848-24 |
| 2021 | Endometriose | Bayer AG | 5 Monate | 4 | EudraCT-2020-003131-16 |
| 2017 | Alzheimer | Biogen Idec Research Limited | 18 Monate | 55 | EudraCT-2015-000967-15 |
| 2004 | Depression | GlaxoSmithKline PLC | 8 Monate | 31 | GDCT0259903 |
| 2021 | Grippe-Impfung | Seqirus UK Limited | 3 Wochen | 61 | EudraCT-2021-001721-40 |
| 2016 | Reizdarmsyndrom | Laves-Arzneimittel GmbH | 4 Months | 11 | EudraCT-2011-001743-78 |
| 2004 | Depression | Pfizer Inc. | 3 Monate | 27 | EudraCT-2004-000562-13 |
| 2016 | Reizdarmsyndrom | SymbioPharm GmbH | 5 Monate | 33 | EudraCT-2012-002741-38 |
| 2004 | Alzheimer | GlaxoSmithKline PLC | 8 Monate | 2 | EudraCT-2004-000985-12 |
| 2016 | COPD | AstraZeneca PLC | 3 Monate | 31 | EudraCT-2015-005444-33 |
| 2016 | Verhütung | Daiichi Sankyo Deutschland GmbH, Estetra SPRL | 5 Monate | 21 | EudraCT-2013-005164-26 |
| 2004 | RLS (Syndrom der unruhigen Beine) | Boehringer Ingelheim Pharma GmbH & Co. KG | 3 Monate | 49 | GDCT0062955 |
| 2016 | Alzheimer | Boehringer Ingelheim Pharma GmbH & Co. KG | 6 Monate | 16 | EudraCT-2013-005031-24 |
| 2016 | Alzheimer | Boehringer Ingelheim Pharma GmbH & Co. KG | 6 Monate | 1 | EudraCT-2013-005040-28 |
| 2010 | Migräne | Merck Sharp & Dohme LLC | 3 Monate | 27 | EudraCT-2010-019288-13 |
| 2016 | Schmerzbehandlung | ESPERION Therapeutics Inc., Boehringer Ingelheim Pharma GmbH & Co. KG | 7 Monate | 80 | EUdraCT-2015-000404-25 |
| 2003 | Depression | Dr. Willmar Schwabe GmbH & Co. KG | 14 Monate | 58 | k.A. |
| 2015 | Diabetes Mellitus Typ II | AstraZeneca PLC | 4 Monate | 9 | EudraCT-2015-002376-24 |
| 2003 | Alzheimer | Sanofi-Synthelabo | 34 Monate | 15 | k.A. |
| 2016 | Hyperlipidämie | ESPERION Therapeutics Inc. | 6 Monate | 12 | EudraCT-2015-004136-36 |
| 2003 | Depression | H. Lundbeck A/S | 7 Monate | 21 | k.A. |
| 2021 | Untere Rückenschmerzen | Vertanical GmbH | aktiv | 31 | EudraCT-2020-000107-36 |
| 2016 | Sodbrennen (GERD) | Reckitt Benckiser Healthcare (UK) Limited | 5 Monate | 47 | EudraCT-2014-005261-69 |
| 2003 | RLS (Syndrom der unruhigen Beine) | UCB (Schwarz Pharma) | 6 Wochen | 32 | GDCT0063543 |
| 2021 | Gesunde Erwachsene | Roche Diagnostics | 4 Wochen | 175 | k.A. |
| 2016 | Asthma | AstraZeneca PLC | 1 Monat | 10 | EudraCT- 2004-004042-41 |
| 2022 | Allergie (Katzenhaar) | Regeneron Pharmaceuticals Inc. | aktiv | 5 | EudraCT-2021-002089-42 |
| 2016 | Arthrose | PBB Entrepreneur Ltd. | 4 Monate | 56 | GDCT0269718 |
| 2004 | Alzheimer | Johnson & Johnson, Janssen-Cilag | 4 Monate | 5 | k.A. |
| 2021 | RSV-Impfung | Janssen Vaccines & Prevention B.V. | 2,5 Monate | 3 | EudraCT-2021-001909-77 |
| 2016 | Allergie (Gräserpollen) | ALLERGOPHARMA GmbH & Co. KG, Merck KGaA | 2 Monate | 33 | EudraCT- 2015-002409-13 |
| 2003 | Abhängigkeit (Nikotin) | GlaxoSmithKline PLC | 4 Tage | 101 | k.A. |
| 2016 | Depression | Janssen Research & Development, LLC | 10 Monate | 3 | EudraCT-2014-004587-38 |
| 2020 | Alzheimer | Biogen GmbH | 9 Tage | 2 | EudraCT-2019-004368-22 |
| 2016 | Akute Infektionen | Vertex Inc. | 3 Monate | 1 | EudraCT-2014-004068-39 |
| 2021 | COVID-19-Impfung | Bavarian Nordic A/S | 5 Monate | 163 | EudraCT-2021-001393-31 |
| 2015 | COPD | Pearl Therapeutics Ltd. | 4 Monate | 29 | EudraCT-2014-004712-10 |
| 2002 | Migräne | GlaxoSmithKline PLC | 4 Monate | 55 | k.A. |
| 2015 | Fibromyalgie | Daiichi Sankyo Development Ltd | 4 Monate | 5 | EudraCT-2013-005164-26 |
| 2002 | RLS (Syndrom der unruhigen Beine) | Boehringer Ingelheim Pharma GmbH & Co. KG | 3 Monate | 35 | GDCT0062484 |
| 2015 | Abhängigkeit (Nikotin) | Philip Morris Products S.A. | 1 Monat | 13 | k.A. |
| 2002 | RLS (Syndrom der unruhigen Beine) | GlaxoSmithKline PLC | 3 Monate | 16 | GDCT50002921 |
| 2021 | COVID-19 | AiCuris Anti-Infective Cures GmbH | 6 Monate | 14 | EudraCT-2021-000167-69 |
| 2015 | COPD | AstraZeneca PLC | 4 Monate | 31 | EudraCT-2014-004715-37 |
| 2002 | RLS (Syndrom der unruhigen Beine) | GlaxoSmithKline PLC | 2 Wochen | 9 | GDCT0309879 |
| 2022 | Wechseljahrsbeschwerden | Bayer Consumer Care AG | 9 Monate | 21 | EudraCT-2020-004855-34 |
| 2015 | Depression | Alkermes PLC | 6 Monate | 60 | EudraCT-2014-000379-14 |
| 2002 | Schizophrenie | Janssen Research & Development, LLC, Johnson & Johnson | 6 Monate | 7 | k.A. |
| 2021 | Gesunde Erwachsene | Heidelberg ImmunoTherapeutics GmbH | 5 Monate | 35 | k.A. |
| 2014 | COPD | GlaxoSmithKline PLC | 2 Monate | 15 | EudraCT-2014-000611-14 |
| 2002 | Depression | Dr. Willmar Schwabe GmbH & Co. KG | 10 Monate | 13 | k.A. |
| 2020 | Lippenherpes | Heidelberg ImmunoTherapeutics GmbH | 22 Monate | 259 | EudraCT-2020-000926-24 |
| 2014 | COPD | GlaxoSmithKline PLC | 6 Wochen | 12 | EudraCT-2011-005914-12 |
| 2002 | Generalisierte Angststörung | Orion Pharma GmbH | 5 Monate | 35 | k.A. |
| 2020 | Colitis Ulcerosa | Novartis Pharma AG | aktiv | 4 | EudraCT-2019-003113-34 |
| 2014 | COPD | Novartis Pharma GmbH | 2 Monate | 21 | EudraCT-2013-001477-25 |
| 2002 | Soziale Phobie | GlaxoSmithKline PLC | 3 Monate | 25 | k.A. |
| 2020 | Wechseljahrsbeschwerden | Sojournix, Inc | 3 Monate | 24 | EudraCT-2019-002281-12 |
| 2014 | Clostridium difficile-Impfung | Sanofi Pasteur SA | 11 Monate | 6 | EudraCT-2013-000775-32 |
| 2001 | Depression | Servier Laboratories UK Ltd | 3 Monate | 9 | k.A. |
| 2018 | Depression | Janssen Research & Development, LLC | 12 Monate | 40 | EudraCT-2015-005282-22 |
| 2014 | Essstörung (Binge Disorder) | Shire Development LLC | 1 Monat | 1 | EudraCT-2012-004457-88 |
| 2001 | Panikstörung | Pfizer Inc. | 12 Monate | 49 | k.A. |
| 2019 | Erkältung | Enzymatika AB, analyze & realize GmbH | 4 Monate | 90 | k.A. |
| 2016 | Grippe-Impfung | Janssen Research & Development, LLC | 3 Monate | 1 | EudraCT-2014-004068-39 |
| 2013 | COPD | AstraZeneca PLC | 3 Monate | 20 | EudraCT-2013-000116-14 |
| 2002 | RLS (Syndrom der unruhigen Beine) | GlaxoSmithKline PLC | k.A. | 8 | GDCT0310475 |
| 2013 | Herpes Zoster-Impfung | GlaxoSmithKline PLC | 1 Monat | 16 | EudraCT-2015-000965-30 |
| 2000 | Depression | Boehringer Ingelheim Pharma GmbH & Co. KG | 12 Monate | 60 | k.A. |
| 2013 | Obstipation | Ferring B.V. | 6 Monate | 24 | EudraCT-2012-005588-28 |
| 2017 | Migräne | CoLucid Pharmaceuticals, Inc. | 2 Monate | 17 | EudraCT-2015-005689-40 |
| 2006 | Diabetische Neuropathie | UCB (Schwarz Pharma) | 4 Monate | 19 | EudraCT-2005-005788-27 |
| 2013 | COPD | GlaxoSmithKline PLC | 1 Woche | 2 | EudraCT-2011-001644-29 |
| 2017 | Schlafstörung | Eisai Inc. | 10 Monate | 93 | EudraCT-2015-004347-39 |
| 2009 | Alzheimer | Eli Lilly and Company | k.A. | 10 | EudraCT-2008-002758-39 |
| 2013 | Essstörung (Binge Disorder) | Shire Pharmaceuticals Group Plc | 2 Monate | 2 | EudraCT-2012-003310-14 |
| 2017 | Reizdarmsyndrom | Dr. Willmar Schwabe GmbH & Co. KG | 9 Monate | 23 | EudraCT-2014-004702-14 |
| 2012 | Depression | H. Lundbeck A/S, Otsuka Pharmaceutical | 8 Monate | 19 | EudraCT-2012-001380-76 |
| 2017 | Depression | Janssen Research & Development, LLC | 11 Monate | 12 | EudraCT-2016-001929-14 |
| 2012 | Depression | H. Lundbeck A/S | k.A. | 19 | EudraCT-2011-001572-19 |
| 2012 | Depression | Merck Sharp & Dohme LLC | 10 Monate | 5 | EudraCT-2011-005200-15 |
| 2017 | Arthrose | Astellas Pharma Inc. | 1 Monat | 22 | EudraCT-2014-004996-22 |
| 2012 | Depression | Shire Development LLC | 12 Monate | 44 | EudraCT-2011-003018-17 |
| 2017 | Prädiabetes | Glycemicon AG | 15 Monate | 62 | k.A. |
| 2004 | Depression | Pfizer Inc. | k.A. | 19 | EudraCT-2004-000450-23 |
| 2012 | Abhängigkeit (Nikotin) | Pfizer, S.L.U. | 2 Jahre | 371 | EudraCT-2010-022914-15 |
| 2017 | Clostridium difficile-Impfung | Pfizer Inc. | 17 Monate | 30 | EudraCT-2016-003866-14 |
| 2011 | Alzheimer | Sanofi-Synthelabo | k.A. | 6 | k.A. |
| 2012 | COPD | AstraZeneca PLC | 6 Monate | 27 | EudraCT-2011-001524-38 |
| 2016 | Harnwegsinfektion | Repha GmbH Biologische Arzneimittel | 20 Monate | 23 | EudraCT-2013-004653-25 |
| 2012 | Depression | Shire Pharmaceutical Development Ltd | k.A. | 41 | EudraCT-2011-003006-25 |
| 2012 | Reizdarmsyndrom | Laves-Arzneimittel GmbH | 2 Jahre | 72 | EudraCT-2011-001743-78 |
| 2017 | Allergische Rhinitis | ALK-Abelló Arzneimittel GmbH | 1 Monat | 8 | EudraCT-2017-000971-97 |
| 2008 | Grippe-Impfung | GlaxoSmithKline PLC | 2 Monate | 38 | EudraCT-2008-000872-25 |
| 2011 | Alzheimer | Avraham Pharmaceuticals Ltd. | 17 Monate | 32 | EudraCT-2011-004187-30 |
| 2017 | COPD | AstraZeneca PLC, Pearl Therapeutics Ltd. | 1 Monat | 18 | EudraCT-2016-000154-34 |
| 2017 | COPD | Verona Pharma PLC | 4 Monate | 17 | EudraCT-2016-005205-40 |
| 2022 | Borderline-Persönlichkeitsstörung | Oryzon | aktiv | 39 | EudraCT-2020-003469-20 |
| 2011 | Alzheimer | Genentech Inc. | 4 Monate | 6 | EudraCT-2010-021926-37 |
| 2017 | Akute Infektionen | Medicago Inc. | 2 Monate | 92 | EudraCT-2017-001239-38 |
| 2011 | RLS (Syndrom der unruhigen Beine) | UCB Biosciences GmbH | 4 Monate | 47 | EudraCT- 2011-000053-23 |
| 2018 | Alzheimer | Eisai Co., Ltd. | 10 Monate | 17 | EudraCT-2016-003928-23 |
| 2004 | Depression | Eli Lilly and Company | 3 Monate | 56 | GDCT0060310 |
| 2011 | Venöse Insuffizienz | OM PHARMA SA | 4 Monate | 9 | EudraCT-2009-013391-44 |
| 2018 | Schlafstörung | Idorsia Pharmaceuticals Ltd. | 13 Monate | 239 | EudraCT-2017-004642-20 |
| 2007 | Diabetische Neuropathie | Swedish Orphan Biovitrum AB | 2 Monate | 1 | EudraCT-2006-005967-25 |
| 2011 | Psychiatrische Diagnosen, sonstige | Weleda AG | 9 Monate | 201 | EudraCT-2010-024189-23 |
| 2018 | Akute Infektionen | Medicago Inc. | 12 Monate | 61 | EudraCT-2018-001894-26 |
| 2022 | COPD | AstraZeneca PLC | aktiv | 17 | EudraCT-2022-001476-33 |
| 2011 | Diabetes Mellitus Typ II | MetaCure (USA), Inc. | 10 Monate | 3 | EudraCT-2010-020945-28 |
| 2018 | Arthrose | Regeneron Pharmaceuticals Inc. | 9 Monate | 35 | EudraCT-2017-001702-15 |
| 2022 | Lichen simplex chronicus | Kamari Pharma | aktiv | 12 | k. A. |
| 2011 | Depression | Takeda Pharmaceutical Company Ltd. | 5 Monate | 46 | EudraCT-2011-005298-22 |
| 2018 | Nagelpilz | Moberg Pharma AB | 9 Monate | 127 | EudraCT-2016-001204-39 |
| 2022 | Abhängigkeit (Nikotin) | Philip Morris Products S.A. | aktiv | 18 | k. A. |
| 2011 | COPD | GlaxoSmithKline PLC | 9 Monate | 21 | EudraCT-2010-021802-39 |
| 2018 | Schlafstörung | Janssen Research & Development, LLC | 4 Monate | 32 | EudraCT-2017-000980-33 |
| 2022 | Grippe-Impfung | Moderna | aktiv | 119 | EudraCT-2022-001638-12 |
| 2011 | Hypertonie | Institut de Recherches Internationales Servier | 6 Monate | 5 | EudraCT-2010-020945-28 |
| 2018 | Prämenstruelles Syndrom | Asarina Pharma AB | 17 Monate | 91 | EudraCT-2017-000822-37 |
| 2023 | Bluthochdruck | Alnylam Pharmaceuticals | aktiv | 9 | EudraCT-2021-003776-13 |
| 2011 | Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (Erwachsene) | Novartis Pharmaceuticals | 4 Monate | 70 | EudraCT-2011-004668-31 |
| 2018 | Uterusmyom | Bayer AG | 10 Monate | 11 | EudraCT-2016-002855-48 |
| 2011 | Depression | AstraZeneca PLC | 5 Monate | 18 | EudraCT-2010-019925-33 |
| 2016 | Nagelpilz | Polichem S.A. | 4 Monate | 59 | EudraCT-2015-000561-31 |
| 2011 | Belastungsstörung | Dr. Willmar Schwabe GmbH & Co. KG | 4 Monate | 31 | EudraCT-2010-022114-12 |
| 2011 | Diabetes Mellitus Typ II | Boehringer Ingelheim Pharma GmbH & Co. KG, Eli Lilly and Company | 15 Monate | 18 | EudraCT-2010-021375-92 |
| 2015 | COPD | Novartis Pharma Services AG | 4 Monate | 15 | EudraCT-2013-003127-11 |
| 2014 | Diabetes Mellitus Typ II | Hanmi Pharm.Co.,Ltd. | 5 Monate | 1 | EudraCT-2013-004250-13 |
| 2010 | Erkältung | Enzymatika AB, analyze & realize GmbH, Leiber GmbH | 1 Monat | 60 | k.A. |
| 2013 | Depression | Forest Research Institute | 12 Monate | 25 | EudraCT-2012-001950-25 |
| 2012 | COPD | Allergan PLC, Almirall, S.A., AstraZeneca PLC | 6 Monate | 27 | EudraCT-2011-001524-38 |
| 2011 | COPD | GlaxoSmithKline PLC | 6 Monate | 20 | EudraCT-2010-021802-39 |
| 2010 | Grippe-Impfung | Sanofi Pasteur SA, Merck Sharp & Dohme LLC | 2 Monate | 108 | EudraCT-2010-021068-13 |
| 2008 | Generalisierte Angststörung | H. Lundbeck A/S, Takeda Global Research & Development Centre (Europe) Ltd. | 3 Monate | 10 | EudraCT-2008-001766-90 |
| 2008 | Depression | Takeda Global Research & Development Centre (Europe) Ltd. | 8 Monate | 28 | EudraCT-2008-001580-11 |
| 2008 | Diabetes Mellitus Typ II | Eli Lilly and Company | 4 monate | 4 | EudraCT-2008-004207-63 |
| 2010 | Obstipation | Shire Pharmaceuticals Group Plc, Shire-Movetis NV | 32 Monate | 16 | EudraCT-2009-015719-42 |
| 2006 | Metrorrhagie | Bayer Schering Pharma AG | 6 Monate | 11 | EudraCT-2005-004340-32 |
| 2010 | Depression | Sanofi-Aventis Recherche & Développement | 7 Monate | 33 | EudraCT-2009-010339-42 |
| 2006 | Morbus Parkinson | Axxonis Pharma AG | 2 Monate | 1 | EudraCT-2006-003732-30 |
| 2006 | RLS (Syndrom der unruhigen Beine) | Boehringer Ingelheim Pharma GmbH & Co. KG | 3 Monate | 4 | EudraCT-2005-005225-54 |
| 2003 | Diabetes Mellitus Typ II | GlaxoSmithKline PLC | 8 Monate | 5 | k.A. |
| 2010 | Depression | GlaxoSmithKline PLC | 4 Monate | 22 | EudraCT-2009-010339-42 |
| 2017 | Psoriasis | Novartis Pharma Services AG | 4 Monate | 4 | EudraCT-2015-005170-38 |
| 2009 | Abhängigkeit (Alkohol) | H. Lundbeck A/S | 11 Monate | 121 | EudraCT-2007-002315-92 |
| 2017 | Hyperlipidämie | ESPERION Therapeutics Inc., AstraZeneca PLC | 2 Monate | 4 | EudraCT-2016-004115-12 |
| 2015 | Depression | Alkermes PLC | 5 Monate | 14 | EudraCT-2014-000380-41 |
| 2017 | Depression | Janssen Research & Development, LLC | 3 Monate | 12 | EudraCT-2016-001929-14 |
| 2009 | Depression | H. Lundbeck A/S | 2 Monate | 6 | EudraCT-2007-001871-13 |
| 2018 | Schlafstörung | Idorsia Pharmaceuticals Ltd. | 13 Monate | 16 | EudraCT-2017-004644-38 |
| 2009 | Alzheimer | Institut de Recherches Internationales Servier | 7 Monate | 7 | k.A. |
| 2018 | Depression | Janssen-Cilag GmbH | 3 Monate | 32 | EudraCT-2017-000980-33 |
| 2009 | Diabetes Mellitus Typ II | Novartis Pharma Services AG | 7 Monate | 6 | EudraCT-2008-002758-39 |
| 2019 | Depression | Janssen Research & Development, LLC | 5 Monate | 14 | EudraCT-2019-000695-41 |
| 2009 | RLS (Syndrom der unruhigen Beine) | Pfizer Inc. | 6 Monate | 16 | EudraCT-2008-005889-32 |
| 2019 | Reizdarmsyndrom | Cosmo Pharmaceuticals NV | 13 Monate | 62 | EudraCT-2016-004977-42 |
| 2009 | Diabetes Mellitus Typ II | Boehringer Ingelheim Pharma GmbH & Co. KG | 8 Monate | 2 | EudraCT-2008-008296-33 |
| 2019 | Herzinfarkt | Novartis Pharmaceuticals | 8 Monate | 35 | EudraCT-2018-003786-34 |
| 2009 | Arthrose | Eli Lilly and Company | 4 Monate | 12 | EudraCT-2009-010008-27 |
| 2018 | Diabetes Mellitus Typ II | Novo Nordisk A/S | 4 Monate | 4 | EudraCT-2017-003219-20 |
| 2019 | Statin-Unverträglichkeit | ESPERION Therapeutics Inc. | 9 Tage | 3 | EudraCT-2016-003485-11 |
| 2019 | Übergewicht | Novo Nordisk A/S | 21 Monate | 34 | Eudra CT-2017-003380-35 |
| 2009 | Depression | Takeda Global Research & Development Centre (Europe) Ltd. | 1 Monat | 49 | EudraCT-2008-001581-91 |
| 2019 | Schlafstörung | Idorsia Pharmaceuticals Ltd. | 4 Monate | 7 | EudraCT-2017-004644-38 |
| 2009 | Schlafstörung | GlaxoSmithKline PLC | 2 Monate | 29 | EudraCT-2008-006345-72 |
| 2019 | Akute Infektionen | Sanofi Pasteur SA | 6 Wochen | 99 | EudraCT-2019-000655-14 |
| 2019 | Alopecia Areata | Pfizer Inc. | 4 Monate | 7 | EudraCT-2018-001714-14 |
| 2008 | Herpes Zoster-Impfung | Merck Sharp & Dohme LLC | 8 Monate | 844 | EudraCT-2007-004020-20 |
| 2019 | Atopische Dermatitis | Pfizer Inc. | 3 Monate | 8 | EudraCT-2018-003050-24 |
| 2008 | Hypertonie | Novartis Pharma Services AG | 4 Monate | 18 | EudraCT-2006-006068-44 |
| 2019 | Hyperhidrose | Dr. August Wolff GmbH & Co. KG Arzneimittel | 5 Monate | 108 | EudraCT-2017-004534-29 |
| 2008 | Angsterkrankung (GAD) | Takeda Pharmaceutical Company Ltd. | 2 Monate | 7 | EudraCT-2008-001766-90 |
| 2019 | Herpes Genitalis | Heidelberg ImmunoTherapeutics GmbH | 11 Monate | 108 | EudraCT-2019-000880-26 |
| 2008 | Alzheimer | Eli Lilly and Company | 1 Monat | 3 | EudraCT-2008-002758-39 |
| 2019 | Psoriasis | Pfizer Inc. | 4 Wochen | 4 | EudraCT-2018-003051-38 |
| 2019 | Reizdarmsyndrom | Repha GmbH Biologische Arzneimittel | 18 Monate | 4 | EudraCT-2019-000245-12 |
| 2019 | Reizdarmsyndrom | SymbioPharm GmbH | 22 Monate | 17 | EudraCT-2018-004626-28 |
| 2008 | Reizdarmsyndrom | Menarini Group | 3 Monate | 24 | EudraCT-2008-000214-71 |
| 2019 | Depression | Allergan Inc | 8 Monate | 8 | EudraCT-2018-002782-19 |
| 2008 | Überaktive Blase (OAB) | Pfizer Inc. | 4 Monate | 18 | EudraCT-2007-006451-39 |
| 2020 | Tetanus-Diphtherie-Pertussis-Impfung | Vakzine Projekt Management GmbH | 8 Wochen | 506 | EudraCT-2019-002706-46 |
| 2008 | Migräne | Merck Sharp & Dohme LLC | 3 Monate | 55 | EudraCT-2007-002667-28 |
| 2008 | Untere Rückenschmerzen | Eli Lilly and Company | 6 Monate | 12 | EudraCT-2008-002248-40 |
| 2008 | Depression | Sanofi-Aventis Recherche & Développement | 6 Monate | 29 | EudraCT-2007-003863-31 |
| 2008 | Diabetes Mellitus Typ II | Merck Sharp & Dohme LLC | 1 Monat | 4 | EudraCT-2007-000145-35 |
| 2020 | Depression | Janssen-Cilag International NV | 4 Wochen | 3 | EudraCT-2019-002992-33 |
| 2010 | Depression | H. Lundbeck A/S, Takeda Global Research & Development Centre (Europe) Ltd. | 9 Monate | 43 | EudraCT-2008-001580-11 |
| 2008 | Weibliche Sexuelle Dysfunktion | Bayer Schering Pharma AG | 4 Monate | 13 | Eudract-2006-004397-27 |
| 2020 | Hitzewallungen | Sojournix Inc. | 3 Monate | 24 | EudraCT-2019-002281-12 |
| 2008 | Hyperlipidämie | Merck Sharp & Dohme LLC | 2 Monate | 33 | EudraCT-2011-001007-12 |
| 2008 | Hypertonie | Takeda Pharmaceutical Company Ltd. | 2 Monate | 10 | EudraCT-2007-002583-10 |
| 2007 | Weibliche Sexuelle Dysfunktion | Boehringer Ingelheim Pharma GmbH & Co. KG | 11 Monate | 60 | EudraCT-2007-000032-68 |
| 2020 | Tuberkulose-Impfung | Vakzine Projekt Management GmbH | 6 Monate | 195 | EudraCT-2020-001675-33 |
| 2007 | Depression | GlaxoSmithKline PLC | 10 Monate | 36 | EudraCT-2005-003400-11 |
| 2020 | Alopecia Areata | Pfizer Inc. | 3 Monate | 4 | EudraCT-2019-001084-71 |
| 2007 | Depression | Sanofi-Aventis Recherche & Développement | 10 Monate | 36 | EudraCT-2004-002328-16 |
| 2007 | Depression | Institut de Recherches Internationales Servier | 10 Monate | 16 | EudraCT-2006-004716-48 |
| 2007 | Schlafstörung | Sanofi-Aventis Recherche & Développement | 12 Monate | 14 | EudraCT-2006-004942-18 |
| 2018 | Prädiabetes | Novo Nordisk A/S | 7 Monate | 4 | EudraCT-2017-003219-20 |
| 2016 | Fibromyalgie | Daiichi Sankyo Development Ltd | 6 Monate | 28 | EudraCT-2013-005161-40 |
| 2007 | Polyneuropathie | Grünenthal GmbH | 4 Monate | 8 | EudraCT-2006-003132-29 |
| 2016 | Verhütung | Mithra Pharmaceuticals, Estetra SPRL | 4 Monate | 21 | EudraCT-2015-003150-40 |
| 2007 | Polyneuropathie | Grünenthal GmbH | 4 Monate | 8 | EudraCT-2006-003132-29 |
| 2007 | Hypertonie | Daiichi Sankyo Europe GmbH | 19 Monate | 19 | EudraCT-2006-003877-28 |
| 2015 | Arthrose | Pro Bono Bio International Trading Ltd. | 4 Monate | 56 | GDCT0269718 |
| 2007 | RLS (Syndrom der unruhigen Beine) | Boehringer Ingelheim Pharma GmbH & Co. KG | 4 Monate | 34 | EudraCT-2006-006431-42 |
| 2014 | Übergewicht | Hanmi Pharm.Co.,Ltd. | k.A. | 52 | EudraCT-2013-004251-21 |
| 2007 | Migräne | Merck Sharp & Dohme GmbH | 5 Monate | 35 | EudraCT-2006-006187-35 |
| 2014 | Essstörung (Binge Disorder) | Shire Development LLC | 1 Monat | 1 | EudraCT-2012-003313-34 |
| 2007 | Generalisierte Angststörung | Sanofi-Aventis Recherche & Développement | 6 Monate | 16 | EudraCT-2006-002253-71 |
| 2007 | Depression | Pierre Fabre Médicament | 5 Monate | 11 | EudraCT-2006-002404-34 |
| 2013 | Herpes Zoster-Impfung, Grippe-Impfung | GlaxoSmithKline PLC | k.A. | 16 | EudraCT-2013-000372-15 |
| 2006 | Soziale Phobie | GlaxoSmithKline PLC | 5 Monate | 16 | EudraCT-2006-003597-10 |
| 2010 | Diabetes Mellitus Typ II | Boehringer Ingelheim Pharma GmbH & Co. KG | 6 Monate | 10 | EudraCT-2009-013157-15 |
| 2010 | RLS (Syndrom der unruhigen Beine) | Mundipharma GmbH | k.A. | 21 | EudraCT-2009-011107-23 |
